Abstract
There is much debate about what is the correct dose of thyroxine replacement therapy and whether suppression of the serum TSH concentration, when measured by an assay with a lower limit of detection of 0.1 mU/l or less, is a risk factor for osteoporosis. Nor is there agreement about whether patients with subclinical hypothyroidism are at an increased risk of developing ischaemic heart disease. Normalisation of serum TSH in such patients is by no means a universal policy. Increasingly, it is recognised that hypothyroidism may be temporary and may even remit spontaneously after many years of treatment with thyroxine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
